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Objective Iodine-131-labelled meta-iodobenzylguanidine
(131I-mIBG) therapy is an established treatment modality for
relapsed/refractory neuroblastoma, most frequently
administered according to fixed or weight-based criteria. We
evaluate response and toxicity following a dosimetry-based,
individualized approach.
Materials and methods A review of 44 treatments in 25
patients treated with 131I-mIBG therapy was performed.
Patients received 131I-mIBG therapy following relapse
(n= 9), in refractory disease (n= 12), or with surgically
unresectable disease despite conventional treatment
(n= 4). Treatment schedule (including mIBG dose and
number of administrations) was individualized according to
the clinical status of the patient and dosimetry data from
either a tracer study or previous administrations. Three-
dimensional tumour dosimetry was also performed for eight
patients.
Results The mean administered activity was
11089±7222MBq and the mean whole-body dose for a
single administration was 1.79±0.57 Gy. Tumour-absorbed
doses varied considerably (3.70±3.37mGy/MBq). CTCAE
grade 3/4 neutropenia was documented following 82%
treatments and grade 3/4 thrombocytopenia following 71%
treatments. Further acute toxicity was found in 49% of
patients. All acute toxicities resolved with appropriate
therapy. The overall response rate was 58% (complete or
partial response), with a further 29% of patients having
stable disease.
Conclusion A highly personalized approach combining
patient-specific dosimetry and clinical judgement enables
delivery of high activities that can be tolerated by patients,
particularly with stem cell support. We report excellent
response rates and acceptable toxicity following
individualized 131I-mIBG therapy. Nucl Med Commun
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Introduction
Neuroblastoma is an embryonal tumour of childhood
arising from the neural crest. The majority of patients have
high-risk disease at presentation, which is associated with
a poor outcome despite intensive multimodal therapy.
Targeted molecular radiotherapy with iodine-131-labelled
meta-iodobenzylguanidine (131I-mIBG) has been used
for patients with relapsed and refractory disease and as
an induction and consolidation therapy for over 20 years
[1–7], although reported treatment schedules vary widely
and are difficult to standardize because of the wide range
of presentations, including disease status, patient age
and treatment history. An individualized approach to
treatment is therefore required to maximize therapeutic
potential.
Although 131I-mIBG is usually administered either as a
fixed activity [8] or according to patient weight [9–11], an
alternative approach is to modify the administration
according to a prescribed whole-body absorbed dose
(WBD), which offers the possibility to deliver large
activities and to maximize the absorbed doses delivered
to disease sites without unnecessary toxicity [12,13].
Administrations can be further increased with stem cell
support. It has been shown previously that the prescribed
WBD can be delivered accurately and correlates closely
with haematological toxicity, thereby acting as a surrogate
biomarker for red marrow absorbed dose [14].
Data presented previously at the Annual Congress of the EANM, October 2013;
Lyon, France, and published as an abstract in EANM abstract book.
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The aim of this study was to evaluate the response,
toxicity and long-term outcome of 131I-mIBG therapy in
the treatment of refractory and relapsed neuroblastoma
on the basis of an individualized approach: administra-
tions were tailored to patients according to their bioki-
netics in addition to their clinical status at the time of
131I-mIBG therapy including age, stage, previous thera-
pies, site(s) of disease and response to previous therapies.
Materials and methods
Ethical considerations
131I-mIBG therapy is considered a standard treatment
option in patients with relapsed and refractory neuro-
blastoma. For all patients who received 131I-mIBG ther-
apy, clinical details were examined in an institutional
multidisciplinary meeting and consensus on treatment
was reached. Informed written consent was obtained
before therapy from all patients. Institutional review
board approval was obtained for the retrospective col-
lection of clinical data throughout follow-up at our
institution.
Patients
A review was performed of 44 131I-mIBG treatments
administered between 1994 and 2013 in 25 patients with
a histologically proven diagnosis of neuroblastoma.
Patients were considered eligible for 131I-mIBG therapy
if there was greater tumour uptake than in normal liver,
following relapse (n= 9), in refractory disease (n= 12) or
with surgically unresectable disease despite conventional
treatment (n= 4).
A median of two different chemotherapy regimens was
administered before 131I-mIBG therapy (range 1–5). In
addition, 8/25 patients had previously received high-dose
chemotherapy with autologous stem cell rescue and six
patients had previously received external beam radio-
therapy. Patient characteristics are shown in Table 1.
131I-mIBG therapy
Patients were treated in a room specially designed for
radioisotope therapy within the children’s ward. 131I-mIBG
was administered intravenously over 2 h with hydration.
Thyroid protection was provided with potassium iodide.
Blood pressure and heart rate were monitored during the
procedure and for 24 h after treatment. For the first treat-
ment, 15 patients received a tracer study from which the
activity required to deliver a WBD of 2 Gy was calculated.
The initial administered activity for the remaining 10
patients was calculated from a simple weight-based formula
of 444MBq/kg, followed by an adjustment to the admi-
nistered activity according to a measured WBD for sub-
sequent therapies.
The methodology for whole-body dosimetry has been
described previously [14,15]. Briefly, lead-shielded
ceiling-mounted counters (a NaI detector for 123I tracer
studies and a compensated Geiger counter for 131I-mIBG
therapies) were used to acquire whole-body counts. The
first measurement was acquired immediately after
administration and before the first bladder void to obtain
the reading corresponding to 100% activity. Subsequent
readings were taken consistently after the child’s natural
void and were not performed overnight unless the child
woke naturally. Between 40 and 60 readings were
acquired to define multiexponential effective decay
phases. The cumulated activity was determined from
the integral of the curve, extrapolated to infinity. The
absorbed dose was calculated according to the medical
internal radiation dose schema [16] using an S-factor
modified according to patient weight.
Tumour dosimetry
Image data were obtained to calculate tumour-absorbed
doses for eight of the 25 patients. Between three and
eight SPECT acquisitions were performed on con-
secutive days following the treatment depending on
patient availability and remaining activity. Scans were
acquired on a Philips Forte (Philips Medical Systems,
Milpitas, California, USA) or a GE Millennium VG
gamma camera (GE Healthcare, Waukesha, Wisconsin,
USA) using high-energy general-purpose collimators and
a 128× 128 matrix. The same camera was used for all
scans for any given patient. Image processing and
reconstruction were performed with triple energy win-
dow scatter correction (20% photopeak energy window
centred on 364 keV, with a 6% window of the peak on
either side), a uniform attenuation correction (Chang) and
deadtime corrections determined experimentally for each
camera [17]. Reconstructed scans for each patient were
sequentially coregistered to allow 3D voxelized dosi-
metry to be performed using an in-house dosimetry
software package (Qrius) [18]. This software is based on
patient-specific convolution dosimetry calculations at the
voxel level, with 131I absorbed dose voxel kernels gen-
erated using the general-purpose Monte Carlo code
EGSnrc/EGS++ [19]. The radiation spectra of 131I used
to calculate dose voxel kernels were obtained from the
medical internal radiation dose decay scheme [20]. The
image-based 3D dosimetry application provides an
Table 1 Patient characteristics
Characteristics Value
Sex [n/N (%)]
Male 15/25 (60)
Female 10/25 (40)
Median age at diagnosis (range) (months) 53 (5–229)
Median age at first 131I-mIBG therapy (range) (months) 72 (17–241)
Stage at diagnosisa [n/N (%)]
2 3/25 (12)
3 4/25 (16)
4 18/25 (72)
131I-mIBG, 131iodine-labelled meta-iodobenzylguanidine.
aStage according to the International Neuroblastoma Staging System.
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absorbed dose map of consecutive therapies from which
dose volume histograms (DVH) were derived.
Toxicity
Acute toxicity was defined as any consequence arising
from the point of administration until neutrophil count
recovery to greater than 1. Acute and long-term treatment
toxicity was assessed in all patients by electronic record
and case note review. In patients for whom data were
available (those whose blood counts were monitored at
our institution after 131I-mIBG therapy), haematological
toxicity was graded according to common terminology for
adverse events criteria version 4.0.
Response assessment, follow-up and survival analysis
Following 131I-mIBG therapy, response was assessed by
a combination of diagnostic 131I-mIBG scanning and
cross-sectional imaging (computed tomography or MRI),
which was chosen in accordance with the baseline ima-
ging modality to enable a direct comparison. Imaging was
reviewed by at least two radiologists and consensus
response was classified according to the International
Neuroblastoma Risk Classification definition of response.
Overall survival (OS) analysis was carried out using the
Kaplan–Meier method and 1-year OS and median OS
calculated. Any further therapy administered to con-
solidate 131I-mIBG response was also recorded.
Statistical analysis
Statistical analysis was carried out with GraphPad Prism
software (version 6.00; GraphPad Software Inc., La Jolla,
California, USA) using a two-tailed t-test for paired data
(Wilcoxon matched-pairs signed rank test in the case of
nonparametric data). A double-sided P value of less than
0.05 was considered significant.
Results
Whole-body dosimetry
The 131I-mIBG activity administered and WBD for each
patient are shown in Table 2. The mean administered
activity was 11089MBq (range 3539–32871MBq, SD
7222). The mean 131I-mIBG WBD was 1.79 Gy (range
0.93–3.51, SD 0.57). The median interval between
treatments was 67 days (range 15–1134 days, interquartile
range 45–94). The use of tracer-based and weight-based
methods to prescribe a therapeutic administration
enabled considerably higher activities to be delivered
than is standardly the case with fixed activity adminis-
trations, although as reported previously, both methods
slightly overestimated the absorbed whole-body dose
delivered during therapy [15]. There was no difference
between WBD predicted from a previous therapy and the
WBD delivered (P= 0.28), thus indicating the predictive
power of consecutive therapies.
Tumour dosimetry
A representation (studies no. 2, 20 and 25) of patient
tumour dosimetry utilizing the 3D dosimetry tool is
shown in Fig. 1. The generated 3D absorbed dose maps
with isodose curves enable DVH to be produced to
evaluate the spatial heterogeneity of absorbed dose fol-
lowing therapy.
Tumour-absorbed doses were calculated for eight
patients and are summarized in Fig. 2. The mean
tumour-absorbed dose delivered was 43.7 ± 27.5 Gy,
whereas the mean liver and kidney doses were 5.7 ± 1.4
and 2.5 ± 0.4 Gy, respectively. Allowing for the uncer-
tainty in the dosimetry, the absorbed doses delivered
were consistent. Absorbed dose ratios between con-
secutive therapies are summarized in Table 3.
One patient received three (study no. 20) and one
received five (study no. 2) treatments. For the first
patient, tumour uptake decreased with consecutive
Table 2 Administered activities and whole-body absorbed dose
Study number AA (MBq) Weight (MBq/kg) WBD (Gy)
1a 6611 398 1.70
1b 6605 398 1.61
2a 10 524 357.9 1.00
2b 15 673 517.2 1.37
2c 19 811 649.5 1.62
2d 19 723 644.5 2.2
2e 13 988 466.3 1.13
3a 29 378 391.2 1.78
3b 32 710 352.5 1.12
4 9834 480 1.66
5 3539 281 1.14
6 20 823 458 1.64
7 5559 505 1.94
8a 8243 292.3 1.41
8b 9961 348.3 1.67
9a 6893 393.8 1.59
9b 9363 535 2.22
10a 4775 477.5 1.98
10b 4900 490 1.92
11a 8797 472.95 3.36
11b 8652 465.7 3.51
12a 6889 551.4 2.11
12b 4892 391.4 1.55
13a 6400 345.9 1.75
13b 6417 329.1 1.82
14a 21 066 322.6 1.00
14b 32 871 483.4 2.12
15 13 457 497 2.46
16a 5321 273.8 0.93
16b 15 733 815.2 2.11
17a 6941 341.9 1.83
17b 6572 315.5 1.71
18 11 652 433 2.28
19 9358 307 1.45
20a 7766 413.1 1.35
20b 11 227 578.7 1.83
20c 9270 501 1.47
21a 6701 446.7 1.76
21b 6397 412.7 1.62
22 6144 361 1.11
23 14 538 434 1.62
24a 7636 406.2 3.25
24b 5271 289.1 2.26
25 9060 458 1.96
AA, administered activities; WBD, whole-body absorbed dose.
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therapies, with the final therapy receiving three times
less than the initial therapy, while absorbed tumour dose
ratios also decreased (Table 3). The second patient
showed very similar tumour-absorbed dose ratios for all
therapies, showing that tumour uptake per cumulated
activity for all therapies was very similar [Table 3, missing
data for study no. 2: AA ratio (T4/T3) 1.0; (T5/T4) 0.8;
and tumour dose ratio (T4/T3) 1.2 ± 0.6; (T5/T4)
1.6 ± 1.0].
Toxicity
Common terminology for adverse events grade 3/4 neu-
tropenia was observed following 18/22 (82%) treatments
and grade 3/4 thrombocytopenia was observed following
19/24 (71%) treatments. Autologous stem cell transplant
was administered following 131I-mIBG therapy in 14/24
patients. In addition to the haematological toxicity, fur-
ther acute toxicity was documented following 21/43
(49%) treatments. With the exception of four treatments,
Fig. 1
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Table 3 Absorbed tumour dose ratios for consecutive therapies (T)
T2/T1 T3/T2
Study
number AA ratio
Tumour
uptake
ratio
Tumour
dose ratio AA ratio
Tumour
uptake
ratio
Tumour
dose ratio
2 1.5 1.0 1.5 ±0.9 1.3 0.5 0.6 ±0.4
4 1.1 0.8 0.9 ±0.4 – – –
9 1.4 0.4 0.6 ±0.2 – – –
11 1.0 1.3 1.3 ±0.2 – – –
14 1.6 1.3 2.1 ±0.9 – – –
18 1.4 0.3 0.4 ±0.2 – – –
20 1.4 0.6 0.9 ±0.3 0.8 0.4 0.4 ±0.1
AA, administered activity.
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all acute toxicity involved either culture negative fever or
documented infection. Of the four patients who had
nonfever/infection-related complications, two patients
experienced parotitis, one patient had a hypertensive
episode and one patient complained of back pain. All
acute toxicities resolved with appropriate therapy. With
respect to potentially vulnerable target organs such as the
liver, kidneys and thyroid gland, one patient with a
transient fever had an associated transaminitis, although
no long-term target organ toxicity was observed in any
patient. Only one patient, who did not receive stem cell
rescue, experienced prolonged thrombocytopenia.
Response
Data were available on response in 24/25 patients
(Table 4). Two patients achieved complete remission
(CR) after 131I-mIBG therapy. The first patient remained
in CR for 11 months before relapse (is alive at the time of
writing with disease 16 months after 131I-mIBG therapy).
The second patient developed a relapse 6 months after
131I-mIBG therapy and subsequently died of disease.
Two patients with partial response (PR) following
131I-mIBG therapy subsequently achieved CR after fur-
ther consolidation therapy. One patient who had pre-
viously received multiple lines of chemotherapy, surgery
and high-dose therapy for metastatic neuroblastoma
developed a localized recurrence that was surgically
unresectable. She received five cycles of 131I-mIBG
therapy with a continued PR after each cycle, and then
further treatment with surgical resection, radiotherapy
and cis-retinoic acid treatment. She remains alive and
disease free after 6 years of follow-up. The second
patient had a surgically unresectable localized disease
despite multiple previous lines of chemotherapy. PR
following 131I-mIBG therapy enabled surgical resection.
This was consolidated with radiotherapy and she remains
alive and disease free 12 years since the diagnosis. The
median OS was 18.6 months (95% confidence interval
10.4–26.9), with a 1-year OS of 65% (95% confidence
interval 48–88%). The median follow-up was 44 months
(Fig. 3). Six patients were alive with disease at last
follow-up (median follow-up from 131I-mIBG therapy
12 months, range 4–32 months), whereas 16 patients are
known to have died from disease. The median time from
the last 131I-mIBG therapy to death was 12 months (range
2–82 months).
Discussion
Cumulative evidence from institutional reports and some
early phase trials has established 131I-mIBG therapy as a
standard treatment option in patients with relapsed and
refractory neuroblastoma [2,8,9,13]. There has also been
limited use of 131I-mIBG as part of first-line treatment [4,
7]. However, to date, there are currently no published
randomized-controlled trials of 131I-mIBG therapy for
neuroblastoma at any stage of treatment [21]. To max-
imize the therapeutic potential of 131I-mIBG therapy,
well-designed clinical trials incorporating dosimetry are
needed. A WBD approach for 131I-mIBG therapy as fol-
lowed here enables safe delivery of considerably higher
activities than are standardly provided with fixed
administrations and can be used to deliver reproducible
therapy results on a patient-specific basis [14,22].
Patients with stage III or stage IV neuroblastoma present
with tumours of varying sizes and uptake distributions.
There is a wide interpatient variation in the absorbed
doses delivered to tumours, although these are consistent
between consecutive therapies. As yet, there is no clearly
defined methodology to incorporate DVHs in patient
specific planning or to compare DVHs for individual
therapies or to relate to outcome. However, it is clear that
dose heterogeneity could affect the outcome of sub-
sequent therapies and may partially explain the variation
in responses. In light of this, a 3D dosimetry approach
where DVHs are taken together with tumour-absorbed
dose as well as dose-limiting criteria provides a reason-
able method to help plan patient-specific treatment and
should be used as a guideline to inform subsequent
therapies.
It is difficult to make direct comparisons of trials of
131I-mIBG therapy in neuroblastoma as the study groups
are very heterogeneous and treatment protocols, includ-
ing administration and concomitant therapy, are highly
variable. 131I-mIBG therapy is often administered with a
fixed or weight-based activity and with these techniques,
Table 4 INRC response
INRC response n (%)
Complete remission 2 (8.3)
Partial response 12 (50)
Stable disease 7 (29.2)
Progressive disease 2 (8.3)
Mixed response 1 (4.2)
INRC, international neuroblastoma risk classification.
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response rates (PR and CR) vary between 30 and 56% [1,
8,23]. Within this context, our response rate of 58%, with
88% of patients having stable disease or better following
131I-mIBG therapy, is noteworthy. Our data also support
a previous study showing that a dosimetry-based
approach to augment mIBG intensity may improve
response rates [13]. It is also noteworthy that in our ser-
ies, in two cases, a CR was achieved following either
surgery or radiotherapy consolidation after mIBG therapy
and that in several cases, the duration of response
was long.
Administrations based on fixed activities must inevitably
be limited according to the most vulnerable of patients.
This can lead to undertreatment of the majority. As
found in this study, an individualized approach, on the
basis of patient pharmacokinetics, will often result in the
administration of higher activities. The capacity to
include stem cell support and concomitant chemotherapy
necessitates a multidisciplinary approach and specialized
care as detailed in the European Association of Nuclear
Medicine guidelines [24].
As this report is a retrospective collation of data from
patients who received individualized 131I-mIBG therapy
schedules on the basis of their clinical features and
dosimetry, there are a number of inherent limitations.
Our patient group was heterogeneous in many ways; they
had different disease stages and tumour burdens, had
received various different previous chemotherapy regi-
mens and 131I-mIBG therapy was used under several
different clinical scenarios. However, although the het-
erogeneity in our patient group makes drawing direct
comparisons with other series difficult, this is a true
reflection of the diverse nature of the clinical situations
where 131I-mIBG therapy is applied in standard clinical
practice.
Neuroblastoma has an extremely variable clinical picture
with respect to site(s) of presentation, tumour biology
and disease aggressiveness. In infants with metastatic
disease, their disease may spontaneously regress.
However, metastatic disease in older patients is asso-
ciated with rapid progression and a poor prognosis. Other
patients may have surgically unresectable localized dis-
ease compressing vital structures, but with differentiated
histology and little propensity to metastasize. In such a
heterogeneous group of patients, an adaptive approach
that incorporates adjustment of dose and schedule,
according to clinical judgement, on the basis of a patient’s
individual needs and dosimetry may maximize the
potential benefit to the patient.
A limitation of our study is that there is a significant
amount of missing data specifically on haematological
toxicity. This is because patients are referred for
131I-mIBG therapy from a wide geographical area and
blood counts following therapy are monitored at the
patients’ local institution. This is a common situation
with this relatively rare and highly specialized treatment
and indicates the need for a Europe-wide initiative to
ensure data collection. Nevertheless, our reported hae-
matological toxicity is as expected following 131I-mIBG
therapy and previous work from our institution has shown
a clear correlation between the absorbed whole-body
dose and haematological toxicity [14]. Data on non-
haematological toxicity are more complete because of a
‘shared care’ system, whereby the treating centre is
notified by local hospitals of any admission or problems
requiring intervention. Further nonhaematological toxi-
cities observed in our patients were all resolved with
appropriate treatment and no long-term effects were
found.
In summary, excellent response rates have been obtained
in our institution following individualized 131I-mIBG
therapy while keeping toxicity within acceptable limits.
Our data support the use of patient-specific dosimetry in
future clinical trials to maximize the efficacy of
131I-mIBG therapy.
Conclusion
131I-mIBG therapy is a safe and effective treatment for
relapsed or refractory neuroblastoma. A highly persona-
lized approach, combining clinical judgment with
patient-specific dosimetry, can be used to safely max-
imize therapeutic efficacy. Further multicentre clinical
trials are essential to optimize the treatment and to
determine its place within the patient pathway.
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